Dupuytren’s Disease

Dupuytren’s contracture — what it is, how it forms, and why it occurs more often, earlier, and more severely in people with hemochromatosis.

Dupuytren’s disease may look like a local hand problem that often starts with a small nodule or a tight band in the palmar fascia. Over time it leads to progressive finger flexion and loss of function. Importantly, in some patients it is a warning sign of deeper metabolic disturbances — including hemochromatosis.

Dupuytren’s — more than just a hand issue

Dupuytren’s contracture develops due to disordered fibrosis. Key drivers are hyperactive fibroblasts and excess collagen production, causing firm nodules and cords under the skin. The symptoms are local, but the roots can be systemic or genetic.

Hemochromatosis — a disease with many faces

Mutations in the HFE gene (especially C282Y) lead to a deficiency of hepcidin — the hormone that controls iron flow. The result is chronic oxidative stress and inflammation that promote tissue fibrosis, including in the palmar fascia.

How iron overload fosters contracture

In hemochromatosis there is fibroblast proliferation and overproduction of type III collagen in the palmar fascia. This directly leads to nodules and cords, limiting finger extension and resulting in a persistent contracture.

Numbers that stand out

  • Up to 50% of people with hereditary hemochromatosis may exhibit signs of Dupuytren’s disease.
  • In HH, symptoms tend to appear earlier and progress faster than in the general population.

What research suggests

HFE mutations may influence not only iron metabolism but also the immune system and cytokine profiles. In the future, hepcidin modulation could help curb pathological fibrosis — not only in the liver but in other tissues as well.

What this means for patients and clinicians

Diagnosis

  • Early hand contracture (especially in younger patients) should prompt evaluation for hemochromatosis.
  • In HH, it’s reasonable to periodically assess hand function and disease progression.

Treatment

  • Optimizing iron balance (e.g., therapeutic phlebotomy) may slow progression.
  • In advanced cases, consider procedural therapies (needle aponeurotomy, fasciotomy, collagenase injections).

Dupuytren’s disease is not only a hand problem. In people with hemochromatosis it may be an early marker of systemic iron dysregulation — a chance for earlier diagnosis and more effective treatment.

Did you find it useful?

This portal is for informational and educational purposes only. It does not constitute medical advice and cannot replace consultation with a qualified physician.

All articles